EBS
NYSE · Biotechnology
Emergent Biosolutions Inc
$8.00
-0.14 (-1.72%)
Open$8.22
Previous Close$8.14
Day High$8.32
Day Low$7.90
52W High$14.06
52W Low$5.62
Volume—
Avg Volume979.3K
Market Cap412.77M
P/E Ratio—
EPS$-0.24
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+238.5% upside
Current
$8.00
$8.00
Target
$27.08
$27.08
$18.81
$27.08 avg
$37.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 697.84M | 800.36M | 356.03M |
| Net Income | 49.41M | 51.00M | -80,261,545 |
| Profit Margin | 7.1% | 6.7% | -22.5% |
| EBITDA | 143.72M | 156.59M | -95,339,299 |
| Free Cash Flow | — | — | -67,766,487 |
| Rev Growth | -12.8% | -12.8% | +7.9% |
| Debt/Equity | 1.09 | 1.09 | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |